GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » 3-Year FCF Growth Rate

InVivo Therapeutics Holdings (FRA:04I) 3-Year FCF Growth Rate : 79.40% (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings 3-Year FCF Growth Rate?

InVivo Therapeutics Holdings's Free Cash Flow per Share for the three months ended in Sep. 2023 was €-0.69.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 79.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 79.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 57.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of InVivo Therapeutics Holdings was 84.80% per year. The lowest was -724.80% per year. And the median was 15.90% per year.


Competitive Comparison of InVivo Therapeutics Holdings's 3-Year FCF Growth Rate

For the Biotechnology subindustry, InVivo Therapeutics Holdings's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's 3-Year FCF Growth Rate falls into.



InVivo Therapeutics Holdings 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


InVivo Therapeutics Holdings  (FRA:04I) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


InVivo Therapeutics Holdings 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (FRA:04I) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines